Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (292)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (10)
Health technology evaluations (9)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (292)
Apply filters
Showing 1 to 50 of 292
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
Technology appraisal guidance
TBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
Technology appraisal guidance
TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]
Technology appraisal guidance
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Technology appraisal guidance
TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533
Technology appraisal guidance
TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Technology appraisal guidance
TBC
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
Technology appraisal guidance
11 December 2024
ALXN1840 for treating Wilson disease TS ID 9950
Technology appraisal guidance
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Technology appraisal guidance
TBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]
Technology appraisal guidance
TBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]
Technology appraisal guidance
18 December 2024
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Technology appraisal guidance
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Technology appraisal guidance
TBC
Asunercept for treating glioblastoma [1301]
Technology appraisal guidance
TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Technology appraisal guidance
TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable ID6218
Technology appraisal guidance
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Technology appraisal guidance
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]
Technology appraisal guidance
TBC
Atogepant for preventing migraine [ID5090]
Technology appraisal guidance
15 May 2024
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Technology appraisal guidance
TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]
Technology appraisal guidance
TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
Technology appraisal guidance
TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
Technology appraisal guidance
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Technology appraisal guidance
TBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Technology appraisal guidance
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Technology appraisal guidance
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Technology appraisal guidance
TBC
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Technology appraisal guidance
TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Technology appraisal guidance
TBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
Technology appraisal guidance
TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Technology appraisal guidance
TBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]
Technology appraisal guidance
TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Technology appraisal guidance
20 November 2024
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
Technology appraisal guidance
TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Technology appraisal guidance
13 November 2024
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370
Technology appraisal guidance
TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Technology appraisal guidance
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Technology appraisal guidance
23 October 2024
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Technology appraisal guidance
TBC
Current page
1
2
3
4
5
6
Page
1
of
6
Next page
Results per page
10
25
50
All
Back to top